Amgen Inc (AMGN · NASDAQ)

Amgen shares closed at $385.65, up 1.5% on the day but down 10.6% over the past month, with RSI at 27 and volume running 2.9x the 20-day average. The company has beaten earnings estimates in all four of its last quarters, including the June quarter's $6.29 versus $5.60 expected, while revenue grew 9.5% year over year to $38.09B TTM and earnings jumped 64.9%. Quality metrics remain strong—71.9% gross margin, 35.5% operating margin, and 91.5% ROE—though leverage sits at 3.3x debt/EBITDA on $57.30B of total debt against $13.99B in cash. The analyst target of $387.69 sits just above the current price, and recent coverage highlighted Amgen's dividend growth profile relative to Merck alongside a modest fair-value lift to $388.03.